Bone metabolism biomarkers (BMB) in hormone sensitive prostate cancer (HSPC): Results from SWOG S1216, a phase III trial of androgen deprivation therapy (ADT) +/- orteronel

P. N. Lara; E. Mayerson; E. Gertz; C. Tangen; A. Goldkorn; M. van Loan; M. Hussain; S. Gupta; J. Zhang; P. Twardowski; D. I. Quinn; N. J. Vogelzang; I. Thompson; N. Agarwal

doi:10.1093/annonc/mdy284.010

Bone metabolism biomarkers (BMB) in hormone sensitive prostate cancer (HSPC): Results from SWOG S1216, a phase III trial of androgen deprivation therapy (ADT) +/- orteronel

P. N. Lara, E. Mayerson, E. Gertz, C. Tangen, A. Goldkorn, M. van Loan, M. Hussain, S. Gupta, J. Zhang, P. Twardowski, D. I. Quinn, N. J. Vogelzang, I. Thompson, N. Agarwal

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	viii275-viii276
Journal	Annals of oncology : official journal of the European Society for Medical Oncology
Volume	29
DOIs	https://doi.org/10.1093/annonc/mdy284.010
State	Published - Oct 1 2018

ASJC Scopus subject areas

Hematology
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/annonc/mdy284.010

Cite this

Lara, P. N., Mayerson, E., Gertz, E., Tangen, C., Goldkorn, A., van Loan, M., Hussain, M., Gupta, S., Zhang, J., Twardowski, P., Quinn, D. I., Vogelzang, N. J., Thompson, I., & Agarwal, N. (2018). Bone metabolism biomarkers (BMB) in hormone sensitive prostate cancer (HSPC): Results from SWOG S1216, a phase III trial of androgen deprivation therapy (ADT) +/- orteronel. Annals of oncology : official journal of the European Society for Medical Oncology, 29, viii275-viii276. https://doi.org/10.1093/annonc/mdy284.010

@article{95d824df704b4de0bd732044a2c75358,

title = "Bone metabolism biomarkers (BMB) in hormone sensitive prostate cancer (HSPC): Results from SWOG S1216, a phase III trial of androgen deprivation therapy (ADT) +/- orteronel",

author = "Lara, {P. N.} and E. Mayerson and E. Gertz and C. Tangen and A. Goldkorn and {van Loan}, M. and M. Hussain and S. Gupta and J. Zhang and P. Twardowski and Quinn, {D. I.} and Vogelzang, {N. J.} and I. Thompson and N. Agarwal",

year = "2018",

month = oct,

day = "1",

doi = "10.1093/annonc/mdy284.010",

language = "English (US)",

volume = "29",

pages = "viii275--viii276",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

}

Lara, PN, Mayerson, E, Gertz, E, Tangen, C, Goldkorn, A, van Loan, M, Hussain, M, Gupta, S, Zhang, J, Twardowski, P, Quinn, DI, Vogelzang, NJ, Thompson, I & Agarwal, N 2018, 'Bone metabolism biomarkers (BMB) in hormone sensitive prostate cancer (HSPC): Results from SWOG S1216, a phase III trial of androgen deprivation therapy (ADT) +/- orteronel', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 29, pp. viii275-viii276. https://doi.org/10.1093/annonc/mdy284.010

Bone metabolism biomarkers (BMB) in hormone sensitive prostate cancer (HSPC): Results from SWOG S1216, a phase III trial of androgen deprivation therapy (ADT) +/- orteronel. / Lara, P. N.; Mayerson, E.; Gertz, E. et al.
In: Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, 01.10.2018, p. viii275-viii276.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Bone metabolism biomarkers (BMB) in hormone sensitive prostate cancer (HSPC)

T2 - Results from SWOG S1216, a phase III trial of androgen deprivation therapy (ADT) +/- orteronel

AU - Lara, P. N.

AU - Mayerson, E.

AU - Gertz, E.

AU - Tangen, C.

AU - Goldkorn, A.

AU - van Loan, M.

AU - Hussain, M.

AU - Gupta, S.

AU - Zhang, J.

AU - Twardowski, P.

AU - Quinn, D. I.

AU - Vogelzang, N. J.

AU - Thompson, I.

AU - Agarwal, N.

PY - 2018/10/1

Y1 - 2018/10/1

UR - http://www.scopus.com/inward/record.url?scp=85081531077&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85081531077&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdy284.010

DO - 10.1093/annonc/mdy284.010

M3 - Article

C2 - 32136632

SN - 0923-7534

VL - 29

SP - viii275-viii276

JO - Annals of Oncology

JF - Annals of Oncology

ER -

Lara PN, Mayerson E, Gertz E, Tangen C, Goldkorn A, van Loan M et al. Bone metabolism biomarkers (BMB) in hormone sensitive prostate cancer (HSPC): Results from SWOG S1216, a phase III trial of androgen deprivation therapy (ADT) +/- orteronel. Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Oct 1;29:viii275-viii276. doi: 10.1093/annonc/mdy284.010

Bone metabolism biomarkers (BMB) in hormone sensitive prostate cancer (HSPC): Results from SWOG S1216, a phase III trial of androgen deprivation therapy (ADT) +/- orteronel

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this